MBX Biosciences, Inc. Common Stock
MBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.12 | -0.95 | 0.00 |
| FCF Yield | -9.03% | -4.26% | -3.13% |
| EV / EBITDA | -8.33 | -20.57 | -28.38 |
| Quality | |||
| ROIC | -26.45% | -43.83% | -60.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.98 | 0.88 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -73.03% | -36.26% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.72 | 0.86 | 0.92 |
| Interest Coverage | 0.00 | 0.00 | -67.28 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -7,980.64 | -3,233.85 | -6,361.43 |